Fresenius Kabi Oncology (Delisted) financials and balance sheet

BSE: 532545

Formerly Dabur Pharma

Last traded ₹132.50 on 2 Jan 2014

Delisted on 10 Jan 2014.

6 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Fresenius Kabi Oncology annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 1 of the 6 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2009, the company's revenue for that year, ₹275 Cr, differs from its quarters added, ₹299 Cr.

Results for the year to Mar 2013

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue596
  2. Operating expenses−453
  3. Operating profit143
  4. Depreciation−26
  5. Other income+1.8
  6. Finance costs+2.6
  7. Profit before tax122
  8. Tax−34
  9. Net profit81

Profit and loss

Standalone, ₹ crore, years to March.Fresenius Kabi Oncology quarterly results

₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Revenue from operations241275421412524596
215304325316457453
Materials and goods bought6098119135215161
Operating profit before depreciation26−29979667143
Operating margin10.8%−10.6%22.9%23.3%12.9%24.0%
Depreciation and amortisation51213172426
Operating profit after depreciation21−41847943117
Other income17–6612
Finance costs822191813−3
Profit before tax30−63716732122
636211334
Net profit149−7880495181
Net margin62.0%−28.2%19.0%11.9%9.7%13.5%

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Earnings per share₹9.53−₹4.96₹5.07₹3.11₹3.22₹5.09
Diluted earnings per share₹9.52−₹4.96₹5.07₹3.11₹3.22₹5.09
Market cap at the year end (₹ crore)1,0145761,9491,4122,4041,710

Ratios

Standalone, years to March.

RatioMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Revenue growth––53.2%−2.2%27.1%13.7%
Operating profit growth–––−0.7%−29.7%112.0%
Net profit growth–––−38.6%3.5%58.2%
Earnings per share growth–––−38.7%3.5%58.1%
Interest cover2.6–4.34.43.3−45.0
Interest cover is left blank for the year to Mar 2009: operating profit after depreciation is a loss, and a loss covers no interest bill. Revenue growth is left blank for the year to Mar 2009: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2013.

Measure5 years3 years
Revenue growth, yearly rate19.9%12.3%
Profit growth, yearly rate−11.6%0.2%
Operating margin, average14.5%20.0%
Net margin, average5.2%11.7%
Interest cover, average−8.2−12.4

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2010Mar 2011Mar 2012Mar 2013
Effective tax ratePublished threshold 17.16 per cent8.2830.8342.0328.14
A threshold marked as ours has no published figure; it is the line we read the check against.